cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Fate Therapeutics Inc
14 own
12 watching
Current Price
$0
$-0.35
(-6.4%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
537.1M
52-Week High
52-Week High
37.13
52-Week Low
52-Week Low
4.02
Average Volume
Average Volume
0.38M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization537.1M
icon52-Week High37.13
icon52-Week Low4.02
iconAverage Volume0.38M
iconDividend Yield--
iconP/E Ratio--
What does the Fate Therapeutics Inc do?
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy that consists of adaptive memory NK cells; engineered hnCD16 induced pluripotent stem cells (iPSC)-derived natural killer cell therapy candidates for hematologic/solid tumors; and engineered chimeric antigen receptor iPSC-derived T cell therapy product candidates for hematologic/solid tumors. The company's immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; and ToleraCyte for the treatment of autoimmune and inflammatory diseases; engineered iPSC-derived CD34+ cell therapy for immune disorders. Fate Therapeutics, Inc. has a research collaboration and license agreement with Memorial Sloan Kettering Cancer Center to develop off-the-shelf T-cell immunotherapies; and strategic research collaboration and license agreement with Juno Therapeutics, Inc. to identify small molecule modulators that enhance the function of T cells. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.
Read More
How much money does Fate Therapeutics Inc make?
News & Events about Fate Therapeutics Inc.
Benzinga
1month ago
read more...
Globe Newswire
1month ago
SAN DIEGO, May 02, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ: CRBU) Johnson Fistel, LLP is investigating potential claims on behalf of Caribou Biosciences, Inc. ("Caribou" or the "Company") (NASDAQ: CRBU) against certain of its officers and directors. If you are a current, long-term...
Zolmax
2 months ago
StockNews.com lowered shares of Fate Therapeutics (NASDAQ:FATE Get Rating) from a hold rating to a sell rating in a research note released on Tuesday . FATE has been the subject of several other research reports. Bank of America cut Fate Therapeutics from a buy rating to an underperform rating in a ...
Globe Newswire
2 months ago
NEW YORK, March 30, 2023 (GLOBE NEWSWIRE) -- Sotera Health Co. (NASDAQ: SHC) Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Companys made false and misleading representations concerning ...
Ticker Report
2 months ago
Shares of Fate Therapeutics, Inc. (NASDAQ:FATE Get Rating) have been given a consensus rating of Hold by the twenty-three analysts that are currently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell rating, fourteen have assigned a ...
Frequently Asked Questions
Frequently Asked Questions
What is Fate Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Fate Therapeutics Inc shares?
plus_minus_icon
How can I buy Fate Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Fate Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Fate Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Fate Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Fate Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Fate Therapeutics Inc?
plus_minus_icon
What percentage is Fate Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Fate Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$-0.35
(-6.4%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Kura Oncology Inc
Kura Oncology Inc
$13.73
$-0.20 (-1.40 %)
Vericel Corporation
Vericel Corporation
$34.09
$-0.46 (-1.35 %)
Mesoblast
Mesoblast
$3.52
$-0.07 (-2.09 %)
Anavex Life Sciences Corp.
Anavex Life Sciences Corp.
$9.38
$0.00 (0.00 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Kura Oncology Inc
Kura Oncology Inc
$13.73
$-0.20 (-1.40 %)
Vericel Corporation
Vericel Corporation
$34.09
$-0.46 (-1.35 %)
Mesoblast
Mesoblast
$3.52
$-0.07 (-2.09 %)
Anavex Life Sciences Corp.
Anavex Life Sciences Corp.
$9.38
$0.00 (0.00 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00